Corbus Pharmaceuticals Holdings, Inc. (CRBP)
3.07
+0.21
(+7.34%)
USD |
NASDAQ |
Nov 06, 16:00
3.06
-0.01
(-0.33%)
After-Hours: 20:00
Corbus Pharmaceuticals Holdings Research and Development Expense (Quarterly) : 31.18M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.18M |
| March 31, 2026 | 19.82M |
| December 31, 2025 | 18.41M |
| September 30, 2025 | 20.86M |
| June 30, 2025 | 15.19M |
| March 31, 2025 | 15.64M |
| December 31, 2024 | 8.787M |
| September 30, 2024 | 10.81M |
| June 30, 2024 | 6.865M |
| March 31, 2024 | 5.762M |
| December 31, 2023 | 6.980M |
| September 30, 2023 | 6.550M |
| June 30, 2023 | 4.249M |
| March 31, 2023 | 13.39M |
| December 31, 2022 | 6.243M |
| September 30, 2022 | 4.108M |
| June 30, 2022 | 2.500M |
| March 31, 2022 | 3.286M |
| December 31, 2021 | 5.764M |
| September 30, 2021 | 8.696M |
| June 30, 2021 | 11.27M |
| March 31, 2021 | 10.72M |
| December 31, 2020 | 16.11M |
| September 30, 2020 | 27.52M |
| June 30, 2020 | 30.69M |
| Date | Value |
|---|---|
| March 31, 2020 | 23.95M |
| December 31, 2019 | 23.96M |
| September 30, 2019 | 22.15M |
| June 30, 2019 | 22.18M |
| March 31, 2019 | 21.78M |
| December 31, 2018 | 15.78M |
| September 30, 2018 | 12.81M |
| June 30, 2018 | 10.26M |
| March 31, 2018 | 9.765M |
| December 31, 2017 | 8.287M |
| September 30, 2017 | 5.622M |
| June 30, 2017 | 5.764M |
| March 31, 2017 | 6.366M |
| December 31, 2016 | 5.380M |
| September 30, 2016 | 4.316M |
| June 30, 2016 | 3.567M |
| March 31, 2016 | 2.174M |
| December 31, 2015 | 1.823M |
| September 30, 2015 | 1.635M |
| June 30, 2015 | 1.707M |
| March 31, 2015 | 0.7234M |
| December 31, 2014 | 0.5716M |
| September 30, 2014 | 0.4526M |
| June 30, 2014 | 0.1694M |
| March 31, 2014 | 0.0619M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Heron Therapeutics, Inc. | 2.702M |
| Tonix Pharmaceuticals Holding Corp. | 19.42M |
| Karyopharm Therapeutics, Inc. | 28.96M |
| Minerva Neurosciences, Inc. | 5.156M |
| Ocugen, Inc. | 12.50M |